

Oxelumab

Cat. No.:	HY-P99408
CAS No.:	1186098-83-8
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Oxelumab (R 4930) is a human monoclonal antibody against the OX40 ligand (OX40L). Oxelumab can be used for the research of asthma ^[1] .									
In Vitro	<p>Oxelumab (10 µg/mL; 3 d) represses cell proliferation of NK cells^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Natural Killer (NK) cell lines</td> </tr> <tr> <td>Concentration:</td> <td>10 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>3 days</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell proliferation of NK cells.</td> </tr> </table>		Cell Line:	Natural Killer (NK) cell lines	Concentration:	10 µg/mL	Incubation Time:	3 days	Result:	Inhibited cell proliferation of NK cells.
Cell Line:	Natural Killer (NK) cell lines									
Concentration:	10 µg/mL									
Incubation Time:	3 days									
Result:	Inhibited cell proliferation of NK cells.									
In Vivo	<p>Oxelumab (5 and 30 mg/kg; i.p., once daily for twice) affects the concentrations of IL-6 and the frequencies of splenic human effector memory T cells and switched B cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>NSG mice with PBMCs from UC patients with simple clinical colitis activity index (SCCAI)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>5 and 30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 5 and 30 mg/kg, once daily, on days 6 and 13</td> </tr> <tr> <td>Result:</td> <td>Reversed the ethanol-induced colon dilated and the lost of distinct pattern of pellets. Decreased the level of IL-6 and increased the concentrations of glutamic acid. Reduced frequencies of splenic human effector memory T cells and switched B cells.</td> </tr> </table>		Animal Model:	NSG mice with PBMCs from UC patients with simple clinical colitis activity index (SCCAI) ^[1]	Dosage:	5 and 30 mg/kg	Administration:	Intraperitoneal injection; 5 and 30 mg/kg, once daily, on days 6 and 13	Result:	Reversed the ethanol-induced colon dilated and the lost of distinct pattern of pellets. Decreased the level of IL-6 and increased the concentrations of glutamic acid. Reduced frequencies of splenic human effector memory T cells and switched B cells.
Animal Model:	NSG mice with PBMCs from UC patients with simple clinical colitis activity index (SCCAI) ^[1]									
Dosage:	5 and 30 mg/kg									
Administration:	Intraperitoneal injection; 5 and 30 mg/kg, once daily, on days 6 and 13									
Result:	Reversed the ethanol-induced colon dilated and the lost of distinct pattern of pellets. Decreased the level of IL-6 and increased the concentrations of glutamic acid. Reduced frequencies of splenic human effector memory T cells and switched B cells.									

REFERENCES

[1]. Youngblood BA, et al. AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity

against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice. *Int Arch Allergy Immunol.* 2019;180(2):91-102.

[2]. Kweon S, et al. Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21. *Front Immunol.* 2019 Apr 24;10:879.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA